Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study.

Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. · 2019

Read Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. by Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6593623.txt.

Introduction

Coupland and co-authors study whether anticholinergic drugs raise the risk of dementia. Their nested case-control study appears in JAMA Internal Medicine. The data come from a large English primary care database. Cases were 58,769 patients with dementia. Matched controls numbered 225,574 people. Prescriptions were tracked up to twenty years back. The year before diagnosis was excluded to limit bias. Total exposure was summed by drug class.

Links with raised risk appeared for several classes. Anticholinergic antidepressants were one such class. Drugs for Parkinson's disease and psychosis drugs did too. Bladder drugs and epilepsy drugs also showed links. The links held after adjusting for other factors. The authors urge care when prescribing these drugs to older adults.

Catalog record

CREATORCoupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6593623

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Anticholinergic Drug Exposure and the Risk of Dementia By Carol A. C. Coupland, Trevor Hill, Tom Dening, Richard Morriss, Michael Moore, Julia Hippisley-Cox Published in: JAMA Internal Medicine DOI: 10.1001/jamainternmed.2019.0677 ABSTRACT Key Points Question Is the risk of dementia among persons 55 years or older associated with the use of different types of anticholinergic medication? Findings In this nested case-control study of 58 769 patients with a diagnosis of dementia and 225 574 matched controls, there were statistically significant associations of dementia risk with exposure to anticholinergic antidepressants, antiparkinson drugs, antipsychotic drugs, bladder antimuscarinics, and antiepileptic drugs after adjusting for confounding variables. Meaning The associations observed for specific types of anticholinergic medication suggest that these drugs should be prescribed with caution in middle-aged and older adults. INTRODUCTION An estimated 47 million people worldwide were living with dementia in 2015,1 while in the United States around 5.7 million people have Alzheimer dementia.2 Modifiable risk factors, including hypertension, hearing loss, depression, diabetes, and smoking, account for around 35% of dementia cases.1 Anticholinergic drugs are another potentially modifiable risk factor. This broad group of drugs acts by blocking the neurotransmitter acetylcholine in the central and peripheral nervous system and includes some antihistamines, antidepressants, and medications for gastrointestinal and bladder disorders. These medicines can have short-term adverse effects, including confusion and memory loss in older people,3,4,5,6 but it is less certain whether long-term use increases the risk of dementia. Observational studies of anticholinergic drugs and dementia risk7,8,9,10 have generally been relatively small, only assessed short-term exposure, or were subject to recall bias. These studies were also susceptible to protopathic bias because they did not account for anticholinergic drugs being prescribed to treat early symptoms of dementia before diagnosis. A cohort study11 that reduced protopathic bias by excluding prescriptions in the final year of follow-up found that higher cumulative anticholinergic drug use was associated with a significantly increased risk of dementia but had limited power for analysis of separate types of anticholinergic drug. A recent larger study12 found varying risks associated with different types of anticholinergic drugs and concluded that further research should examine individual anticholinergic drug classes. This study was designed to assess the association between cumulative anticholinergic drug use and risk of dementia in a large, representative British population. The study objectives were to estimate dementia risks associated with different types of anticholinergic medication including analyses of prescriptions up to 20 years before diagnosis. METHODS Study Design This was a nested case-control study within a cohort of patients registered with practices in England contributing to the QResearch database (version 41). QResearch is an anonymized research database of more than 30 million individuals in over 1500 general practices that includes data recorded prospectively from routine health care. The data include demographic information, medical diagnoses, prescriptions, referrals, laboratory results, and clinical values. The study was approved in accordance with the agreed procedure with the East Midlands Derby Research Ethics Committee, waiving written informed consent for deidentified patient data. Selection of Cases and Controls The base cohort included patients 55 years and older registered during the study period (January 1, 2004, to January 31, 2016) without a diagnosis of dementia at study entry, defined as the latest of the study start date (January 1, 2004), the patient’s 55th birthday, date of registration with the practice plus 1 year, or date when the practice computer system was installed plus 1 year. The cohort were followed up until the earliest date of death, transfer to another practice, or the study end date (January 31, 2016). Case patients were those diagnosed with dementia during follow-up, identified using clinical codes recorded in the practice records or linked Office of National Statistics death records. Patients with prescriptions for acetylcholinesterase-inhibiting drugs (donepezil, galantamine, memantine, and rivastigmine) but without a recorded diagnosis of dementia were also included because these drugs are licensed only for patients with dementia. Case patients with diagnostic codes for specific subtypes of dementia associated with Huntington disease, Parkinson disease, Creutzfeldt-Jakob disease, or human immunodeficiency virus (HIV) were excluded, as were patients diagnosed with Parkinson disease, Huntington disease, or multiple sclerosis to reduce indication bias. Each case patient was matched to 5 controls by age (within 1 year), sex, general practice, and calendar time using incidence density sampling.13 The index date for controls was the date of diagnosis for their matched case patient. Controls were excluded if they had a diagnosis of Parkinson disease, Huntington disease, or multiple sclerosis. For the primary analyses, case patients and controls were only included if they had at least 11 years of recorded data prior to the index date, so that anticholinergic drug exposure could be assessed over a complete period of 10 years (excluding the 1-year period prior to the index date). Exposures There is incomplete consensus on which drugs are considered as having anticholinergic properties. We used the approach of Gray et al,11 which included drugs identified as having strong anticholinergic properties by the American Geriatrics Society 2012 Beers Criteria Update Expert Panel.14 We also included additional drugs in the Beers 2015 updated list of strong anticholinergic drugs,15 drugs listed as having a high anticholinergic burden in the Anticholinergic Cognitive Burden scale,16 or identified as high-potency anticholinergics in a systematic review,17 and some further drugs identified as having substantial anticholinergic properties in the British National Formulary; these may have been omitted in previous studies owing to their unavailability in the country where the study originated. eTable 1 in the Supplement shows the 56 anticholinergic drugs included in the study with details of their basis for inclusion. We extracted details of prescriptions for the included anticholinergic drugs. To reduce protopathic biases, we did not include prescriptions issued in the year before the index date. In 2 additional analyses, we only included prescriptions issued up to 3 and up to 5 years before diagnosis. The primary exposure variable was total cumulative anticholinergic drug exposure, which combined the different types of anticholinergic medications based on the method used by Gray et al.11 This involved calculating the total dose of each prescription by multiplying the number of tablets prescribed by the dose per tablet (or equivalent for solutions, inhalers, injections, or patches). These values were then divided by minimum effective daily dose values recommended for use in older adults to give a number of standardized daily doses for each prescription. We used minimum effective dose values from the Geriatric Dosage Handbook18 where available, and for the additional drugs we used the lowest recommended dose values (in older people if stated) in the British National Formulary (see eTable 1 in the Supplement). We summed these standardized values over all anticholinergic prescriptions in the exposure time windows of interest to obtain total standardized daily doses (TSDDs) for each patient. We also calculated TSDDs for each type of anticholinergic drug based on its main indication (antihistamines, antidepressants, antivertigo/antiemetic drugs, antiparkinson agents, antipsychotics, bladder antimuscarinics, skeletal muscle relaxants, gastrointestinal antispasmodics, antiarrhythmics, antiepileptic drugs, and antimuscarinic bronchodilators). As a sensitivity analysis we used World Health Organization (WHO)-defined daily dose (DDD) values (https://www.whocc.no/atc_ddd_index/) to standardize the prescribed doses. Confounding Variables We accounted for potential confounding variables identified as risk factors for dementia or indications for anticholinergic drug use,19,20,21,22,23,24,25 including body mass index,

Read the complete text